{"id":"W4310859181","doi":"10.1016/j.jtocrr.2022.100444","title":"First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Merck Sharp and Dohme; Ministère de la Santé et des Services sociaux; Merck","keywords":"Pembrolizumab; Medicine; Carboplatin; Internal medicine; Chemotherapy; Oncology; Confidence interval; Retrospective cohort study; Cancer; Immunotherapy; Cisplatin","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007913405,0.0002011496,0.0008178765,0.0002202562,0.000860277,0.00003224168,0.0001468219,0.0001615504,0.0008350934],"category_scores_gemma":[0.003575026,0.0001462492,0.0003824342,0.0004155849,0.0005802895,0.00008823513,0.0003271129,0.0009098215,0.000004171754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007485118,"about_ca_system_score_gemma":0.001136974,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009579628,"about_ca_topic_score_gemma":0.001909757,"domain_scores_codex":[0.9958211,0.000395826,0.001234353,0.0008062474,0.00112139,0.0006211229],"domain_scores_gemma":[0.9938453,0.003994919,0.0007705407,0.0006539606,0.0003983116,0.0003369674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1608534,0.003971263,0.3868617,0.0006401595,0.001073763,0.004778934,0.000802529,0.00004111862,0.001889646,0.000164007,0.09791201,0.3410115],"study_design_scores_gemma":[0.01291504,0.005813692,0.0985128,0.00003451463,0.00005713428,0.0006236567,0.0002091744,0.0001788785,0.0001641896,0.0005407605,0.8807634,0.0001868295],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9285067,0.001968565,0.00001141893,0.05861572,0.001007984,0.002388008,0.00002306152,0.0000886047,0.007389953],"genre_scores_gemma":[0.9397422,0.006091425,0.0005229739,0.002447022,0.0004984502,0.0008040218,0.00005741763,0.00005418845,0.04978229],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7828513,"threshold_uncertainty_score":0.9143687,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1758482435059359,"score_gpt":0.5244882499617058,"score_spread":0.3486400064557699,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}